COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND

被引：0
|
作者：
Sruamsiri, R. [1 ]
机构：
[1] Takeda Thailand Ltd, Bangkok, Thailand
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.015
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE3
引用
收藏
页码：S2 / S2
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [42] Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation
    Stern, Sean
    Ward, Alexandra J.
    Thibault, Catherine Saint-Laurent
    Camacho, Fernando
    Rahme, Elham
    Naessens, Dominik
    Aumais, Guy
    Bernard, Edmond-Jean
    Bourdages, Raymond
    Cohen, Albert
    Pare, Pierre
    Dyrda, Peter
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) : 27 - 37
  • [43] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Taku Kobayashi
    Masato Hoshi
    Akira Yuasa
    Shoko Arai
    Mitsunobu Ikeda
    Hiroyuki Matsuda
    Seok-Won Kim
    Toshifumi Hibi
    PharmacoEconomics, 2023, 41 : 589 - 604
  • [44] Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review
    Bhandari, Renu
    Ogeyingbo, Opemipo D.
    Kareem, Roaa
    Gyawali, Mallika
    Venkatesan, Nanditha
    Ahmed, Rowan
    Botleroo, Rinky A.
    Elshaikh, Abeer O.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [45] THE COST-EFFECTIVENESS OF ISOTRETINOIN IN PATIENTS WITH MODERATE-TO-SEVERE ACNE VULGARIS
    Shin, J.
    Hay, J.
    VALUE IN HEALTH, 2010, 13 (03) : A146 - A146
  • [46] Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis A single-center experience in Northern China
    Yan, Jing
    Ding, Xueli
    Wu, Jun
    Liu, Ailing
    Fang, Liang
    Xu, Yonghong
    MEDICINE, 2024, 103 (27) : e38759
  • [47] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Katsuyoshi Matsuoka
    Tadakazu Hisamatsu
    Yohei Mikami
    Takayuki Yamamoto
    Satoshi Motoya
    Shinichiro Shinzaki
    Ryuichi Iwakiri
    Kenkichi Sugiura
    Kunihiko Nishimura
    Mika Kajita
    Jovelle L. Fernandez
    Advances in Therapy, 2023, 40 : 2902 - 2914
  • [48] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Mikami, Yohei
    Yamamoto, Takayuki
    Motoya, Satoshi
    Shinzaki, Shinichiro
    Iwakiri, Ryuichi
    Sugiura, Kenkichi
    Nishimura, Kunihiko
    Kajita, Mika
    Fernandez, Jovelle L.
    ADVANCES IN THERAPY, 2023, 40 (06) : 2902 - 2914
  • [49] Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners
    Norton, Beth-Ann
    Sullivan, Anne
    Senior, Jennifer
    Candela, Ninfa
    Jason, Mary
    Weyant, Katherine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2022, 18 (04): : 438 - 445
  • [50] COST-EFFECTIVENESS OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB AS FIRST-LINE THERAPY FOR ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2018, 154 (06) : S450 - S450
12345